Hydrochlorothiazide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Hydrochlorothiazide
Hydrochlorothiazide: Known uses and market status in Australia
Summary
The TxGNN model produced no candidate with a score of 0.99 or higher for Hydrochlorothiazide, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 5 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| congestive heart failure | official label (curated) |
| heart failure | official label (curated) |
| essential hypertension | licence in another country |
| hypertension | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13409R | Dithiazide | Tablet 25 mg | Valid |
Safety Considerations
The data compiled for this report holds no label-derived warnings or contraindications, so please refer to the TGA-approved Product Information (PI) for these.
- Knowledge-graph contraindication signals (not label text, and they should be verified against the PI): liver failure, liver disease and cirrhosis, kidney disease, pancreatitis, gallbladder disease, peptic ulcer disease, epilepsy, asthma and bronchitis, anxiety and related disorders, porphyria, angioedema (including hereditary and acquired forms), systemic lupus erythematosus, autoimmune haemolytic anaemia, fetal erythroblastosis, myopathy and muscle disease, and familial periodic paralysis.
- Drug interactions: 100 interactions were recorded, and the first 20 are summarised here. Most are rated Moderate, including acarbose, rabeprazole, hydrocortisone, albiglutide, alogliptin, acetohexamide, cholecalciferol, calcifediol, calcitriol, amphotericin B (several formulations), beclomethasone, betamethasone, bisacodyl and bupropion. Doxycycline and atropine are rated Minor.
- Literature safety signal: Case reports describe hydrochlorothiazide-associated pulmonary oedema and drug-induced methaemoglobinaemia.
- Relevance to this prediction: Kidney disease appears among the knowledge-graph contraindication signals, which needs careful consideration for a renal-related indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.